Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Helus Pharma raises $50M; HLP003 enrollment near 90% with Q4 topline

Jun 29, 2026, 7:43 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong near-term catalysts (financing strengthening balance sheet; 88% Phase 3 enrollment; Q4 2026 topline) and regulatory tailwinds for psychedelics could lift HELP, though dilution from the new offering and trial execution risk remain counterpoints.

AI summary

What happened, with direct paths to the underlying reporting

Helus Pharma reported FY2026 results and a $50 million underwritten offering, boosting liquidity for late-stage work. HLP003 APPROACH is 88% enrolled with topline data due in Q4 2026, with EMBRACE under way and EXTEND data planned. The company also reported strong Phase 2 durability for HLP003 and positive signals from HLP004 in GAD, alongside leadership additions and regulatory tailwinds for psychedelics, supporting a potential 2028 FDA NDA.

Helus Pharma closes $50M underwritten offering; strengthens balance sheet for HLP003 EMBRACE.
HLP003 APPROACH enrollment >88%; Q4 2026 topline data; EMBRACE underway, EXTEND long-term data ongoing.
HLP003 Phase 2 shows 12-month durability: ~23-point MADRS reduction; 100% response, 71% remission.
HLP004 Phase 2 in GAD shows ~10-point HAM-A improvement on SOC at 6 weeks.
Leadership updates; White House signals supportive of psychedelics; cash $157.3M; NDA potential 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Helus Pharma raises $50M; HLP003 enrollment near 90% with Q4 topline

Helus Pharma Shares Fall Despite Ph II Results Announcement for HLP004